Primary central nervous system lymphoma in a patient treated with mycophenolate mofetil for lupus nephritis

ABSTRACT Primary central nervous system lymphoma is a rare and aggressive form of extranodal non‐Hodgkin lymphoma, and its occurrence in pharmacologically immunosuppressed patients has increased over the years. Currently, mycophenolate mofetil (MMF) is one of the recommended treatment options for th...

Full description

Saved in:
Bibliographic Details
Published inNeurology and clinical neuroscience Vol. 9; no. 1; pp. 114 - 117
Main Authors García‐Grimshaw, Miguel, Jiménez‐Ruiz, Amado, Vega‐Boada, Felipe Arturo, Falcón‐Antonio, Orlando Emmanuel, Barrera‐Vargas, Ana, Valdés‐Ferrer, Sergio Iván
Format Journal Article
LanguageEnglish
Published Tokyo Wiley Subscription Services, Inc 01.01.2021
Subjects
Case reports
Central nervous system
Lupus
Lupus nephritis
Lymphoma
Mycophenolate mofetil
Mycophenolic acid
Nephritis
Nervous system
Non-Hodgkin's lymphoma
non‐Hodgkin lymphoma
primary central nervous system lymphoma
Systemic lupus erythematosus
Online AccessGet full text

Cover

More Information
Summary:ABSTRACT Primary central nervous system lymphoma is a rare and aggressive form of extranodal non‐Hodgkin lymphoma, and its occurrence in pharmacologically immunosuppressed patients has increased over the years. Currently, mycophenolate mofetil (MMF) is one of the recommended treatment options for the induction and maintenance of lupus nephritis. The evidence regarding the development of PCNSL in patients with systemic lupus erythematosus (SLE) treated with MMF is limited to a few case reports. We present the case of a 40‐year‐old woman with a history of SLE who developed PCNSL while treated with MMF for lupus nephritis and a review of all published cases with this association.
ISSN:2049-4173
2049-4173
DOI:10.1111/ncn3.12457